FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1/h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-02								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* GARDNER JASON				2. Issuer Name and Ticker or Trading Symbol Magenta Therapeutics, Inc. [MGTA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
												X	X Director				Owner		
	GENTA T	irst) (HERAPEUTICS, Y SQUARE	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/10/2020								X	Offic below			belov	r (specify w)
(Street) CAMBR (City))2139 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc Line)	Forn	Form filed by One Reporting Person Form filed by More than One Reporting Person			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/			Execution Date,		3. Transaction Disposed O Code (Instr. 8)		Acquired (A) or f (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		Form (D) o	Form: Direct In (D) or Indirect B (I) (Instr. 4) O	7. Nature of Indirect Beneficial Ownership					
									Code	v	V Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)		tion(s)			(Instr. 4)
Common	Stock			01/10/20)20			S ⁽¹⁾	S ⁽¹⁾ 1		D	\$15.2	25 ⁽²⁾	251	,212	D			
Common Stock														292	2,990		I	By J.P. Gardner Irrevocable Trust	
Common Stock														359),092		I	By P.S. Gardner Irrevocable Trust	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date Execution Date, if any (Month/Day/Year)					ransaction of ode (Instr. Derivative		Expira	te Exer ation D th/Day/		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		De Se (Ir	erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owners Form: Direct (I or Indire (I) (Instr	Ownership	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	or Number of Shares	r					

Explanation of Responses:

- 1. This trade is pursuant to an active 10b5-1 plan.
- 2. This transaction was executed in multiple trades at prices ranging from \$15.10 to \$15.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was

Remarks:

President and Chief Executive Officer

/s/ Zoran Zdraveski, Attorney-01/10/2020 in- Fact for Jason Gardner

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.